ABDX Abingdon Health Plc

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THE PLACING SHARES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OR UNDER THE APPLICABLE SECURITIES LAW OR WITH ANY SECURITIES REGULATORY AUTHORITY OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES OR UNDER THE SECURITIES LAWS OF AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY STATE, PROVINCE OR TERRITORY THEREOF OR ANY OTHER JURISDICTION OUTSIDE THE UNITED KINGDOM AND MAY NOT BE OFFERED, SOLD, PLEDGED, TAKEN UP, EXERCISED, RESOLD, RENOUNCED, TRANSFERRED OR DELIVERED, DIRECTLY OR INDIRECTLY, THROUGH CREST OR OTHERWISE, WITHIN, INTO OR FROM CANADA, AUSTRALIA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR THE UNITED STATES, OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, ANY PERSON WITH A REGISTERED ADDRESS IN, OR WHO IS A RESIDENT OR ORDINARY RESIDENT IN, OR A CITIZEN OF SUCH JURISDICTIONS OR TO ANY PERSON IN ANY COUNTRY OR TERRITORY WHERE TO DO SO WOULD OR MIGHT CONTRAVENE APPLICABLE SECURITIES LAWS OR REGULATIONS EXCEPT PURSUANT TO AN APPLICABLE EXEMPTION. ANY SECURITIES OF THE COMPANY WILL ONLY BE OFFERED AND SOLD OUTSIDE OF THE UNITED STATES IN "OFFSHORE TRANSACTIONS" WITHIN THE MEANING OF AND IN RELIANCE ON THE SAFE HARBOUR FROM THE REGISTRATION REQUIREMENTS UNDER THE SECURITIES ACT PROVIDED BY REGULATION S PROMULGATED THEREUNDER.  THE SECURITIES OF THE COMPANY HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE US SECURITIES AND EXCHANGE COMMISSION, ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY IN THE UNITED STATES, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OF THE PLACING OR THE ACCURACY OR ADEQUACY OF THIS PRESENTATION.  ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE IN THE UNITED STATES. SUBJECT TO CERTAIN EXCEPTIONS, THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, ANY NATIONAL, RESIDENT OR CITIZEN OF THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR THE REPUBLIC OF SOUTH AFRICA.

NO PUBLIC OFFERING OF SECURITIES IS BEING MADE IN THE UNITED STATES.

THIS ANNOUNCEMENT, INCLUDING THE APPENDIX, IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR"), AND IS DISCLOSED IN ACCORDANCE WITH THE COMPANY'S OBLIGATIONS UNDER ARTICLE 17 OF MAR. IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

THIS ANNOUNCEMENT INCLUDES STATEMENTS THAT ARE, OR MAY BE DEEMED TO BE, "FORWARD-LOOKING STATEMENTS". THESE FORWARD-LOOKING STATEMENTS CAN BE IDENTIFIED BY THE USE OF FORWARD-LOOKING TERMINOLOGY, INCLUDING THE TERMS "BELIEVES", "ESTIMATES", "FORECASTS", "PLANS", "PREPARES", "ANTICIPATES", "PROJECTS", "EXPECTS", "INTENDS", "MAY", "WILL", "SEEKS", "SHOULD" OR, IN EACH CASE, THEIR NEGATIVE OR OTHER VARIATIONS OR COMPARABLE TERMINOLOGY, OR BY DISCUSSIONS OF STRATEGY, PLANS, OBJECTIVES, GOALS, FUTURE EVENTS OR INTENTIONS. THESE FORWARD-LOOKING STATEMENTS INCLUDE ALL MATTERS THAT ARE NOT HISTORICAL FACTS. THEY APPEAR IN A NUMBER OF PLACES THROUGHOUT THIS ANNOUNCEMENT AND INCLUDE STATEMENTS REGARDING THE COMPANY'S AND THE DIRECTORS' INTENTIONS, BELIEFS OR CURRENT EXPECTATIONS CONCERNING, AMONGST OTHER THINGS, THE COMPANY'S PROSPECTS, GROWTH AND STRATEGY, PLANNED WORK AT THE COMPANY'S PROJECTS AND THE EXPECTED RESULTS OF SUCH WORK. BY THEIR NATURE, FORWARD-LOOKING STATEMENTS INVOLVE RISKS AND UNCERTAINTIES BECAUSE THEY RELATE TO EVENTS AND DEPEND ON CIRCUMSTANCES THAT MAY OR MAY NOT OCCUR IN THE FUTURE. FORWARD-LOOKING STATEMENTS ARE NOT GUARANTEES OF FUTURE PERFORMANCE. THE COMPANY'S ACTUAL PERFORMANCE, ACHIEVEMENTS AND FINANCIAL CONDITION MAY DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED BY THE FORWARD-LOOKING STATEMENTS IN THIS ANNOUNCEMENT. IN ADDITION, EVEN IF THE COMPANY'S RESULTS OF OPERATIONS, PERFORMANCE, ACHIEVEMENTS AND FINANCIAL CONDITION ARE CONSISTENT WITH THE FORWARD-LOOKING STATEMENTS IN THIS ANNOUNCEMENT, THOSE RESULTS OR DEVELOPMENTS MAY NOT BE INDICATIVE OF RESULTS OR DEVELOPMENTS IN SUBSEQUENT PERIODS. ANY FORWARD-LOOKING STATEMENTS THAT THE COMPANY MAKES IN THIS ANNOUNCEMENT SPEAK ONLY AS OF THE DATE OF SUCH STATEMENT AND (OTHER THAN IN ACCORDANCE WITH THEIR LEGAL OR REGULATORY OBLIGATIONS) NEITHER THE COMPANY, NOR ZEUS CAPITAL NOR ANY OF THEIR RESPECTIVE ASSOCIATES, DIRECTORS, OFFICERS OR ADVISERS SHALL BE OBLIGED TO UPDATE SUCH STATEMENTS. COMPARISONS OF RESULTS FOR CURRENT AND ANY PRIOR PERIODS ARE NOT INTENDED TO EXPRESS ANY FUTURE TRENDS OR INDICATIONS OF FUTURE PERFORMANCE, UNLESS EXPRESSED AS SUCH, AND SHOULD ONLY BE VIEWED AS HISTORICAL DATA.

ZEUS CAPITAL, WHICH IS AUTHORISED AND REGULATED IN THE UNITED KINGDOM BY THE FCA, IS ACTING AS NOMINATED ADVISER AND BROKER EXCLUSIVELY FOR THE COMPANY AND NO ONE ELSE IN CONNECTION WITH THE PLACING AND THE CONTENTS OF THIS ANNOUNCEMENT AND WILL NOT REGARD ANY OTHER PERSON (WHETHER OR NOT A RECIPIENT OF THIS ANNOUNCEMENT) AS ITS CLIENT IN RELATION TO THE PLACING NOR WILL IT BE RESPONSIBLE TO ANYONE OTHER THAN THE COMPANY FOR PROVIDING THE PROTECTIONS AFFORDED TO ITS CLIENTS OR FOR PROVIDING ADVICE IN RELATION TO THE CONTENTS OF THIS ANNOUNCEMENT. APART FROM THE RESPONSIBILITIES AND LIABILITIES, IF ANY, WHICH MAY BE IMPOSED ON ZEUS CAPITAL BY THE FSMA OR THE REGULATORY REGIME ESTABLISHED THEREUNDER, ZEUS CAPITAL ACCEPTS NO RESPONSIBILITY WHATSOEVER, AND MAKES NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, AS TO THE CONTENTS OF THIS ANNOUNCEMENT OR ANY OTHER WRITTEN OR ORAL INFORMATION MADE AVAILABLE TO OR PUBLICLY AVAILABLE TO ANY INTERESTED PARTY OR ITS ADVISERS INCLUDING ITS ACCURACY, COMPLETENESS OR VERIFICATION OR FOR ANY OTHER STATEMENT MADE OR PURPORTED TO BE MADE BY IT, OR ON BEHALF OF IT, THE COMPANY OR ANY OTHER PERSON, IN CONNECTION WITH THE COMPANY AND THE CONTENTS OF THIS ANNOUNCEMENT, WHETHER AS TO THE PAST OR THE FUTURE. ZEUS CAPITAL ACCORDINGLY DISCLAIMS ALL AND ANY LIABILITY WHATSOEVER, WHETHER ARISING IN TORT, CONTRACT OR OTHERWISE (SAVE AS REFERRED TO ABOVE), WHICH IT MIGHT OTHERWISE HAVE IN RESPECT OF THE CONTENTS OF THIS ANNOUNCEMENT OR ANY SUCH STATEMENT. THE RESPONSIBILITIES OF ZEUS CAPITAL AS THE COMPANY'S NOMINATED ADVISER UNDER THE AIM RULES FOR COMPANIES AND THE AIM RULES FOR NOMINATED ADVISERS ARE OWED SOLELY TO THE LONDON STOCK EXCHANGE AND ARE NOT OWED TO THE COMPANY OR TO ANY DIRECTOR OR SHAREHOLDER OF THE COMPANY OR ANY OTHER PERSON, IN RESPECT OF ITS DECISION TO ACQUIRE SHARES IN THE CAPITAL OF THE COMPANY IN RELIANCE ON ANY PART OF THIS ANNOUNCEMENT, OR OTHERWISE.  

THE INFORMATION IN THIS ANNOUNCEMENT, WHICH MAY INCLUDE CERTAIN INFORMATION DRAWN FROM PUBLIC SOURCES, DOES NOT PURPORT TO BE COMPREHENSIVE AND HAS NOT BEEN INDEPENDENTLY VERIFIED.

THE CONTENT OF THIS ANNOUNCEMENT HAS NOT BEEN APPROVED BY AN AUTHORISED PERSON WITHIN THE MEANING OF THE FSMA. RELIANCE ON THIS ANNOUNCEMENT FOR THE PURPOSE OF ENGAGING IN ANY INVESTMENT ACTIVITY MAY EXPOSE AN INDIVIDUAL TO A SIGNIFICANT RISK OF LOSING ALL OF THE PROPERTY OR OTHER ASSETS INVESTED. THE PRICE OF SECURITIES AND ANY INCOME EXPECTED FROM THEM MAY GO DOWN AS WELL AS UP AND INVESTORS MAY NOT GET BACK THE FULL AMOUNT INVESTED UPON DISPOSAL OF THE SECURITIES. PAST PERFORMANCE IS NO GUIDE TO FUTURE PERFORMANCE, AND PERSONS NEEDING ADVICE SHOULD CONSULT AN APPROPRIATE INDEPENDENT FINANCIAL ADVISER.

NO PROSPECTUS WILL BE MADE AVAILABLE IN CONNECTION WITH THE MATTERS CONTAINED IN THIS ANNOUNCEMENT AND NO SUCH PROSPECTUS IS REQUIRED (IN ACCORDANCE WITH THE EU PROSPECTUS REGULATION OR THE UK PROSPECTUS REGULATION) TO BE PUBLISHED. THIS ANNOUNCEMENT AND THE TERMS AND CONDITIONS SET OUT HEREIN ARE FOR INFORMATION PURPOSES ONLY AND ARE DIRECTED ONLY AT, UNLESS OTHERWISE AGREED BY ZEUS CAPITAL, PERSONS WHO ARE: (A) PERSONS IN MEMBER STATES WHO ARE QUALIFIED INVESTORS; AND (B) IN THE UNITED KINGDOM, QUALIFIED INVESTORS WHO ARE PERSONS WHO (I) HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS FALLING WITHIN THE DEFINITION OF "INVESTMENT PROFESSIONALS" IN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE "ORDER"); (II) ARE PERSONS FALLING WITHIN ARTICLE 49(2)(A) TO (D) ("HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS, ETC") OF THE ORDER; OR (III) ARE PERSONS TO WHOM IT MAY OTHERWISE BE LAWFULLY COMMUNICATED (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS"). ANY PERSON WHO IS NOT EITHER A QUALIFIED INVESTOR (IF IN THE EEA) OR RELEVANT PERSONS (IF IN THE UNITED KINGDOM) SHOULD NOT ACT OR RELY ON THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT. 

NEITHER THE CONTENT OF THE COMPANY'S WEBSITE NOR ANY WEBSITE ACCESSIBLE BY HYPERLINKS ON THE COMPANY'S WEBSITE IS INCORPORATED IN, OR FORMS PART OF, THIS ANNOUNCEMENT.

Abingdon Health plc

("Abingdon" or "the Company" or "the Group")

Proposed Acquisition and Placing

Notice of General Meeting

Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organisation (CDMO), announces that:

·    it has entered into a conditional agreement to acquire the Compliance Solutions Group, a consultancy business which specialises in meeting regulatory requirements in international IVD and medical device markets for a maximum consideration of up to £3.2 million in cash and shares, with the cash element funded by Abingdon's existing cash resources;

·    it is undertaking a conditional placing to raise gross proceeds of c. £5.2 million via the issue of an aggregate of approximately 53.6 million new Ordinary Shares ("Placing Shares") at a price of 9.75 pence per share ("the Placing Price") to invest in Abingdon's CDMO services and product development;   

·    it is proposing to raise up to an additional £0.5 million by way of a retail offer to provide private and other investors who were not eligible to take part in the Placing with an opportunity to participate in the Fundraising; and

·    up to £3.0 million of the proceeds of the Placing will fund additional product development alongside the Group's patented AppDx® smartphone technology, with up to £1 million being invested over two years to expand the Group's Analytical Laboratory Service, and with the balance to provide working capital.

Zeus Capital Limited is acting as sole broker in relation to the Placing ("Zeus Capital" or the "Broker"). The Company expects to issue the Placing Shares via a conditional placing (the "Placing") being conducted through an accelerated book-build process (the "Bookbuild"), which will be launched immediately following this Announcement. A placing agreement has been entered into today between the Company and the Broker in connection with the Placing (the "Placing Agreement").

The acquisition of the Compliance Solutions Group, comprising Compliance Solutions (Life Sciences) Limited, CS Lifesciences Europe Limited and CS Lifesciences USA Inc. (the "Acquisition"), and the Placing are subject, inter alia, to shareholder approval, with the General Meeting expected to be convened for 10.00 a.m. on 12 August 2024.  

Acquisition highlights

The Compliance Solutions Group specialises in meeting regulatory requirements of its international client base in the UK IVD and medical device markets.  The Compliance Solutions Group's team (currently c.37 employees) provides consultancy services, ranging from:

•                             preparation of technical files for regulatory approvals, including preparing CE-mark, FDA and other regulatory submissions, clinical strategy advice and protocol design and regulatory inspection gap analysis;

•                             design, implementation and maintenance of quality management systems, including GMP and FDA compliance and equipment validation;

•                             technical file and design file reviews, clinical evaluation reports and biological safety evaluations; and

•                             internal audit programmes; supplier audits, pre-audit preparations (e.g. FDA, MHRA, Notified Body, unannounced) and mock Notified Body/FDA audits.

The maximum consideration of £3.2 million comprises:

§ cash of £1.36 million to be paid as to £700,000 on Completion and then 3 equal payments of £220,000 at the end of the first, second and third month following Completion; and

§ the sum of £1.0 million to be satisfied by the issue of 9,216,590 Ordinary Shares in Abingdon ("Consideration Shares"); and

§ subject to achieving certain revenue targets in the period starting on the first anniversary of the acquisition and ending on the second anniversary of the Acquisition, an earn out of up to £0.5 million to be satisfied by the issue of such number of further Ordinary Shares as is equal to the earn-out consideration divided by the average of the closing middle market quotations of the Company's Ordinary Shares over the five dealing days ending on the dealing day immediately before the date when the earn-out consideration is agreed or determined in accordance with the terms of the Acquisition Agreement ("Further Consideration Shares"); and

§ an amount in cash equal to the amounts received by Compliance Solutions (Life Sciences) Limited ("CS (LS)") in respect of certain aged debtors in the 24 month period from Completion, subject to a maximum amount of £340,000;

and in addition, the sum of £50,000 will be injected by the Company into CS (LS) by way of loan to facilitate the repayment by CS (LS) of an outstanding director loan balance.

Placing highlights

The Company intends to issue up to c. 53.6million Placing Shares, to raise gross proceeds of up to c. £5.2 million at a price of 9.75 pence per New Ordinary Share.

The use of proceeds is expected to comprise approximately:

•       The Placing is being conducted through an accelerated book-build process, which will open with immediate effect following this Announcement.

•       The Placing Shares, assuming full take-up, will represent approximately 28.2 per cent. of the Company's issued share capital as enlarged by the Acquisition and Placing ("Enlarged Share Capital").

•       The final number of Placing Shares will be agreed by the Broker and the Company at the close of the Bookbuild, and the result will be announced as soon as practicable thereafter.

•       The timing for the close of the Bookbuild and allocation of the Placing Shares shall be at the discretion of Zeus Capital, in consultation with the Company. The Placing is not underwritten.

•       The Appendix to this Announcement (which forms part of this Announcement) contains the detailed terms and conditions of the Placing.

•       The issue of the Placing Shares is subject to, inter alia, the passing of shareholder Resolutions at a General Meeting.

•       The General Meeting is expected to be convened for 10.00 a.m. on 12 August 2024 and will take place at York Biotech Campus, Sand Hutton, York YO41 1LZ.

1.               The Acquisition

The Group's strategy is to provide a comprehensive contract development and manufacturing service to an international in vitro diagnostics and lateral flow diagnostics customer base. Its intention is to provide "all the pieces of the jigsaw" to allow a customer to take a project from concept to commercialisation.

Hence, in addition to providing contract development, scale-up, technical transfer and contract manufacturing solutions, the Group has expanded its offering to include, inter alia, packaging design, kitting, regulatory and quality management system support and analytical laboratory services.

As part of this strategy, the Group recently acquired the IVDeology Group, a UK-based regulatory consultancy, for a maximum consideration of £700,000.

The Board is therefore delighted to announce today the conditional acquisition of the Compliance Solutions Group, comprising Compliance Solutions (Life Sciences) Limited, CS Lifesciences Europe Limited ("CS Europe") and CS Lifesciences USA Inc. ("CS USA") (currently not trading).

The Compliance Solutions Group specialises in meeting regulatory requirements of its international client base in the UK IVD and medical device markets.  The Compliance Solutions Group's team (currently c.37 employees) provides consultancy services, ranging from:

·    preparation of technical files for regulatory approvals, including preparing CE-mark, FDA and other regulatory submissions, clinical strategy advice and protocol design and regulatory inspection gap analysis;

·    design, implementation and maintenance of quality management systems, including GMP and FDA compliance and equipment validation;

·    technical file and design file reviews, clinical evaluation reports and biological safety evaluations; and

·    internal audit programmes; supplier audits, pre-audit preparations (e.g. FDA, MHRA, Notified Body, unannounced) and mock Notified Body/FDA audits.

CS Europe provides EU Responsible Person services to medical device companies. CS USA is currently dormant. 

The Compliance Solutions Group's activities are complementary to those of the Group and increase the depth of the Group's regulatory expertise through the addition of the Compliance Solutions Group's regulatory expertise. Furthermore, there is, in the Board's opinion, the opportunity to cross-sell the Group's services, such as lateral flow development and manufacture and analytical laboratory support, into the Compliance Solutions Group's customer base.

CS (LS)'s recent trading history is highlighted below:

Source: Unaudited Abridged Financial Statements of Compliance Solutions (Life Sciences) Ltd for the year ended 30 June 2023

CS Europe's recent trading history is highlighted below:

Source: Unaudited Abridged Financial Statements of CS Lifesciences Europe Limited for the year ended 31 December 2022

Edwin Lindsay, the Compliance Solutions Group's Managing Director, will continue in that role post Completion and will join Abingdon's executive management team.

The maximum consideration of £3,200,000 comprises:

·    cash of £1.36 million to be paid as to £700,000 on Completion and then 3 equal payments of £220,000 at the end of the first, second and third month following Completion;

·    the sum of £1.0 million to be satisfied by the issue of the Consideration Shares;

·    subject to achieving certain revenue targets in the period starting on the first anniversary of the Acquisition and ending on the second anniversary of the Acquisition, an earn out of up to £0.5 million to be satisfied by the issue of the Further Consideration Shares; and

·    an amount in cash equal to the amounts received by CS (LS) in respect of certain aged debtors in the 24-month period from Completion, subject to a maximum amount of £340,000;

and in addition, the sum of £50,000 will be injected by the Company into CS (LS) by way of loan to facilitate the repayment by CS (LS) of an outstanding director loan balance.

The Consideration Shares and the Further Consideration Shares will be subject to a 12-month lock-in followed by a 12-month orderly market provision.

Completion of the Acquisition Agreement and the issue of the Consideration Shares and the Further Consideration Shares are conditional upon:

·    the Placing Agreement having become unconditional in all respects and not having been terminated in accordance with its terms;

·    the passing of the Resolutions to be proposed at the General Meeting; and

·    Admission (of the Placing Shares) having occurred, (together the "Acquisition Agreement Conditions").

Completion of the Acquisition Agreement will take place no later than five business days after the date when all the Acquisition Agreement Conditions have been satisfied (unless otherwise agreed between the parties).

Should the Acquisition Agreement Conditions not be satisfied by 30 September 2024, the Acquisition and the issue of the Consideration Shares and the Further Consideration Shares will not proceed.

The Company also has a right to terminate the Acquisition Agreement if there is a material breach of a warranty prior to Completion.

The Acquisition Agreement contains certain warranties and indemnities (including a tax covenant) given by the Vendors.

2.              Reasons for the Placing

The Company intends to issue c. 53.6 million Placing Shares, to raise gross proceeds of approximately £5.2 million.

The use of proceeds is expected to comprise approximately:

i)             Product development

The Board proposes to use up to £3.0 million of the proceeds to enhance the Group's product offering through development of lateral flow self-tests alongside use of the Group's patented AppDx® technology - a smartphone based lateral flow test reader.

In addition to the Group's CRO/CDMO and associated routes to market, the Board has identified opportunities for the Group to utilise its in-house scientific skills, assay development experience and infrastructure to develop additional products which are complementary to those of its CDMO customers and its Abingdon Simply Test® range.    

Key opportunities include (i) infectious disease self-testing, which complements current CDMO activity, and (ii) certain other clinical lateral flow self-tests which complement those in the Abingdon Simply Test® range.  

In addition, the use and product-specific development of the Group's AppDx® lateral flow test reader is expected to add further value to these products and increase ease of use for the end-user. Importantly, these new developments will utilise the Group's current and developing routes to market. 

ii)            Expansion to analytical laboratory service

The Board also proposes to use up to £1.0 million of the proceeds of the Placing to strengthen its analytical laboratory service. The Group has been providing this service since 2023 as part of its strategy of providing a comprehensive contract development and manufacturing service and supporting its customers in bringing products to market. The services of an analytical laboratory, which provides a significant contribution to a product's technical file, include:

·    Stability;

·    Specificity;

·    Detection limits;

·    Interference; and

·    Cross-reactivity.

The Placing will allow the Group to expand its in-house analytical laboratory services and also extend these capabilities to a range of other test formats including PCR, LAMP, isothermal amplification assays, antigen and antibody detection immunoassays and other point-of-care assays, in addition to supporting basic research.

3.               Information on the Placing

The issue of the Placing Shares is conditional upon, amongst other things, the passing of the Resolutions to be put to Shareholders at the General Meeting. The Placing Shares are expected to be admitted to trading on AIM on or around 14 August 2024, being the first trading day following the General Meeting.

In connection with the Placing, the Company entered into the Placing Agreement, pursuant to which the Bookrunner, as agent for the Company, conditionally agreed to use its reasonable endeavours to procure subscribers for the Placing Shares. The Placing has not been underwritten by the Bookrunner or any other person.

The Placing Agreement and the issue of the Placing Shares are conditional upon:

·    the entering into of the Acquisition Agreement;

·    the fulfilment by the Company of its obligations to deliver to Zeus Capital certain documents required under the Placing Agreement by the time specified in the Placing Agreement;

·    an AIM application form in respect of the Placing Shares signed on behalf of the Company and all other documents to be submitted therewith having been delivered to the London Stock Exchange;

·    the Circular having been posted to the Company's shareholders by no later than 25 July 2024 (by first class pre-paid mail) in accordance with the articles of association;

·    the Company having complied with all of its other obligations under the Placing Agreement (to the extent that such obligations fall to be performed prior to Admission) and not being in breach of the Placing Agreement save where, in the good faith opinion of Zeus Capital, such non-compliance or breach is not material;

·    no matter having arisen before Admission which would reasonably be expected to give rise to a claim under any of the indemnities given by the Company in the Placing Agreement;

·    the Resolutions being passed at the General Meeting;

·    the Acquisition Agreement not having been terminated prior to Admission;

·    the delivery by the Company to Zeus Capital immediately prior to Admission of the Warranty Certificate in the form set out in the Placing Agreement and signed for and on behalf of the Company by a Director;

·    the Placing Shares having been allotted, subject only to Admission; and Admission occurring by no later than 8.00 a.m. on 14 August 2024 (or such later time and/or date as the Company and Zeus Capital may agree, being not later than 8.00 a.m. on 23 September 2024 (the "Long Stop Date").

Should the conditions in the Placing Agreement not be satisfied, the Placing, the Acquisition and the Retail Offer will not proceed.

The Placing Agreement contains customary warranties from the Company in favour of the Bookrunner in relation to, inter alia, the accuracy of the information in this document and other matters relating to the Group and its business. In addition, the Company has agreed to indemnify the Bookrunner in relation to certain liabilities it may incur in respect of the Placing. The Bookrunner has the right to terminate the Placing Agreement in certain circumstances prior to Admission, in particular, in the event of a breach of the warranties given to the Bookrunner in the Placing Agreement, the occurrence of a force majeure event or a material adverse change affecting the condition, or the earnings or business affairs or prospects of the Group as a whole, whether or not arising in the ordinary course of business.

4.               The Retail Offer

In order to provide private and other investors who were not eligible to have taken part in the Placing with an opportunity to participate in the fundraising and to mitigate an element of dilution, the Company is proposing to raise up to an additional £500,000 (before expenses) by way of a retail offer via Bookbuild (the "Retail Offer") of up to 5,128,205 new Ordinary Shares at the Placing Price following Admission of the Consideration Shares.    

The Retail Offer announcement will be made after admission of the Consideration Shares and will contain further information on how interested parties can participate in the Retail Offer.

For the avoidance of doubt, the Retail Offer is not part of the Placing and is the sole responsibility of the Company. The Bookrunner does not have any responsibilities, obligations, duties or liabilities (whether arising pursuant to any contract, law, regulation, or tort) in relation to the same.

The Company has relied on an available exemption against the need to publish a prospectus approved by the FCA (acting in its capacity as the UK Listing Authority) in respect of the Retail Offer.

5.               Taxation

The Company is seeking to raise funds by the issue of certain Placing Shares (to raise gross proceeds of up to £5.0 million) to VCTs. Such Placing Shares are intended to rank as "eligible shares" for the purposes of VCT investors and a "qualifying holding" for the purposes of an investment by VCTs, pursuant to the relevant respective sections of ITA 2007.

The Company has obtained a written opinion from specialist tax advisers confirming that the Company would, subject to the relevant limits on such issuances, be able to issue part of the Placing Shares as "eligible shares" under the relevant sections of the ITA 2007.

Neither the Company nor the Directors give any warranties or undertakings that VCT reliefs will be granted in respect of Placing Shares issued as VCT qualifying shares pursuant to the Placing. Neither the Company nor the Directors give any warranties or undertakings that VCT reliefs, if granted, will not be withdrawn. If the Company carries on activities beyond those disclosed to HMRC in a prior advance clearance obtained in connection with a previous placing of Ordinary Shares in the Company, then Shareholders may cease to qualify for the tax benefits. Placees must take their own advice and rely on it. 

6.               Financial Update and Outlook

Unaudited revenues for FY 2024 will be c.£6.1 million (FY 2023: £4.0 million) and revenues in the second half of the financial year were 55% ahead of H1 FY 2024.  Cash as of 30 June 2024 was £1.3 million (31 December 2023: £2.0 million).

Cash-burn reduced in H2 2024 compared to H1 2024; and in Q4 2024 cash flow was positive.

The Board anticipates that continued solid revenue growth in FY 2025, along with close management of the Group's operational cost base, will further drive operational profitability improvements. 

Contract services

The Group's CDMO business has seen good revenue traction year-on-year with revenue of £5.5 million in FY 2024, circa 51% ahead of FY 2023 (£3.6 million). Abingdon's CDMO proposition is resonating well with customers across a range of sectors including self-test and point-of-care clinical testing, animal health, plant health and environmental testing. It is particularly pleasing to work with companies across a range of activities including contract development, technical transfer and scale-up, and also regulatory and commercial support.

The Board was pleased to support its CDMO customer, Salignostics Ltd, in securing retail distribution opportunities in the UK, including at Boots, where their innovative saliva-based pregnancy test is being rolled out across 1,300 Boots stores nationwide and online at boots.com.

A number of customers' products were transferred into manufacturing during the year, including Salignostics, LoopDx (sepsis point-of-care test) and Up Front Diagnostics (stroke point-of-care test); and the Group looks forward to supporting them, and its existing manufacturing customers, going forward as these products achieve further regulatory approvals and market penetration.

The Group strengthened its regulatory service capabilities in May 2024 with the acquisition, for up to £700,000, of IVDeology. IVDeology's service capabilities include Quality Management System build, technical file build, auditing and regulatory filing support (FDA, IVDR, CE-marking and UKCA-marking). The acquisition is complementary to Abingdon's existing regulatory service capabilities and provides the Group with strength in depth to support its customers in a regulatory environment undergoing significant change.

Abingdon Products

Abingdon Products achieved revenue of £0.7 million in FY 2024, up 56% compared to £0.4 million in FY 2023. As anticipated at the time of the interim accounts for the six months ended 31 December 2023, the second half saw a stronger performance with revenues in H2 FY 2024 176% ahead of H1 FY 2024. The main driver was the launch in H2 FY 2024 of three lateral flow self-tests under Boots' own-label, Vitamin D, Iron (Ferritin) and Saliva Pregnancy. 

The  Group continues to focus on further opportunities, both in the UK and Europe, to promote own-label solutions to major retailers. In addition, the Abingdon Simply Test® range of self-test products, launched online in July 2022, continues to build and the Group's product range now consist of 16 self-tests. The Group  will continue to explore opportunities to build routes to market in the UK, Ireland and Europe. 

7.               General Meeting

The Board is seeking the approval of Shareholders to allot the Placing Shares, the Consideration Shares, the Further Consideration Shares (based on an issue price equal to that of the Consideration Shares as the actual issue price will be unknown until the end of the earn out period in line with the Acquisition Agreement) and the Retail Offer Shares at the General Meeting. In addition to this specific authority, the Board is also seeking the approval of the Shareholders to give the Directors the additional general authority to allot up to 66% of the Company's current share capital (in line with the authorities and limitations normally sought at each annual general meeting).

The Company's General Meeting will be held at York Biotech Campus, Sand Hutton, York YO41 1LZ at 10 a.m. on 12 August 2024. Further details of the General Meeting will be included in a Circular to Shareholders, to be posted to Shareholders on or around the date of this Announcement.

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

Notes:

1.       Each of the times and dates above are indicative only and are subject to change. If any of the above times and/or dates change, the revised times and/or dates will be notified by the Company to Shareholders by announcement through a regulatory information service.

2.       All of the above times refer to London time unless otherwise stated.

3.       Completion of the Acquisition Agreement is conditional upon Admission and commencement of dealing in the Placing Shares.

4.       The admission and commencement of dealings in the Placing Shares on AIM are conditional on, inter alia, the passing of the Resolutions at the General Meeting.

KEY STATISTICS

Chris Yates, CEO of Abingdon Health plc, commented:

"We are delighted to announce the Placing and Acquisition to support the acceleration of our growth plans.

"The Placing will allow the build-out of our analytical laboratory to provide customers with the verification and validation services that are integral to a technical file build and regulatory submission. Furthermore, the Placing will also enable us to invest in product development to grow our range of self-test lateral flow products with additional innovative proprietary products.

"We are also pleased to announce the acquisition of Compliance Solutions Group, broadening and deepening the regulatory support we can provide customers in navigating the increasingly complex regulatory environment in the UK, Europe, the United States and elsewhere.

"I would like to welcome Edwin Lindsay, Compliance Solutions Group Managing Director, and all Compliance Solutions employees to the Abingdon Health Group."

Enquiries

The person responsible for arranging the release of this announcement on behalf of the Company is Chris Yates, Chief Executive Officer of the Company.

About Abingdon Health plc

Abingdon is a leading lateral flow contract development and manufacturing organisation ("CDMO") offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing. Abingdon has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing; from "idea to commercial success".

The Company's CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon aims to support the increase in need for rapid results across many industries and locations; and produces lateral flow tests in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making and targeted intervention; and can support better outcomes. 

Abingdon'as Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test e-commerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland, such as pharmacy chains.

Founded in 2008, Abingdon is headquartered in York, England.

For more information visit: www.abingdonhealth.com

APPENDIX I

Terms and conditions of the Placing

THIS ANNOUNCEMENT, INCLUDING THE APPENDICES (TOGETHER, THE "ANNOUNCEMENT") AND THE INFORMATION IN IT IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

MEMBERS OF THE PUBLIC ARE NOT ELIGIBLE TO TAKE PART IN THE PLACING. THIS APPENDIX AND THE TERMS AND CONDITIONS SET OUT HEREIN ARE FOR INFORMATION PURPOSES ONLY AND ARE DIRECTED ONLY AT, UNLES OTHERWISE AGREED BY ZEUS CAPITAL: (A) PERSONS WHO ARE IN A MEMBER STATE OF THE EUROPEAN ECONOMIC AREA AND ARE, UNLESS OTHERWISE AGREED BY ZEUS CAPITAL, QUALIFIED INVESTORS; AND/OR (B) IN THE UNITED KINGDOM, PERSONS WHO ARE (I) QUALIFIED INVESTORS; AND "INVESTMENT PROFESSIONALS" WITHIN THE MEANING OF ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (AS AMENDED) (THE "ORDER"); (II) PERSONS FALLING WITHIN ARTICLE 49(2)(A) TO (D) ("HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS, ETC") OF THE ORDER; OR (III) PERSONS TO WHOM IT MAY OTHERWISE BE LAWFULLY COMMUNICATED (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS").

THIS APPENDIX, AND THE TERMS AND CONDITIONS SET OUT HEREIN, IS A FINANCIAL PROMOTION AND IS EXEMPT FROM THE GENERAL RESTRICTION IN SECTION 21 OF FSMA ON THE COMMUNICATION OF INVITATIONS OR INDUCEMENTS TO ENGAGE IN INVESTMENT ACTIVITY, ON THE GROUNDS THAT IT IS ONLY BEING DISTRIBUTED TO RELEVANT PERSONS. ACCORDINGLY, THIS APPENDIX AND THE TERMS AND CONDITIONS SET OUT HEREIN MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO ARE NOT RELEVANT PERSONS. DISTRIBUTION OF THIS ANNOUNCEMENT IN CERTAIN JURISDICTIONS MAY BE RESTRICTED OR PROHIBITED BY LAW. PERSONS DISTRIBUTING THIS ANNOUNCEMENT MUST SATISFY THEMSELVES THAT IT IS LAWFUL TO DO SO. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS APPENDIX AND THE TERMS AND CONDITIONS SET OUT HEREIN RELATE IS AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS. ANY PERSON WHO IS NOT EITHER A QUALIFIED INVESTOR (IF IN THE EEA) OR A RELEVANT PERSON (IF IN THE UNITED KINGDOM) SHOULD NOT ACT OR RELY ON THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT. 

THIS ANNOUNCEMENT IS NOT AN OFFER FOR SALE OR SUBSCRIPTION IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL UNDER THE SECURITIES LAWS OF ANY JURISDICTION. THIS ANNOUNCEMENT DOES NOT ITSELF CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN THE COMPANY. THIS ANNOUNCEMENT IS NOT AN OFFER OF OR SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR SECURITIES IN THE UNITED STATES. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, EXCEPT PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR AS PART OF A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. NEITHER THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION NOR ANY SECURITIES REGULATORY AUTHORITY OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES HAS APPROVED OR DISAPPROVED OF AN INVESTMENT IN THE SECURITIES OR PASSED UPON OR ENDORSED THE MERITS OF THE PLACING OR THE ACCURACY OR ADEQUACY OF THE CONTENTS OF THIS ANNOUNCEMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE IN THE UNITED STATES. NO PUBLIC OFFERING OF SECURITIES IS BEING MADE IN THE UNITED STATES.

EACH PLACEE SHOULD CONSULT WITH ITS OWN ADVISERS AS TO THE LEGAL, TAX, BUSINESS AND RELATED IMPLICATIONS OF AN INVESTMENT IN THE PLACING SHARES AND THE INCOME FROM THEM (IF ANY) MAY GO DOWN AS WELL AS UP AND INVESTORS MAY NOT GET BACK THE FULL AMOUNT INVESTED ON A DISPOSAL OF THEIR SHARES.

The relevant clearances have not been, nor will they be, obtained from the securities commission of any province or territory of Canada; no prospectus has been lodged with or registered by, the Australian Securities and Investments Commission or the Japanese Ministry of Finance or the South African Reserve Bank; and the Placing Shares have not been, nor will they be, registered or qualified for distribution, as applicable under or offered in compliance with the securities laws of any state, province or territory of the United States, Australia, Canada, Japan, New Zealand, or South Africa. Accordingly, the Placing Shares may not (unless an exemption under the relevant securities laws is applicable) be offered, sold, resold or delivered, directly or indirectly, in or into the United States, Australia, Canada, Japan, New Zealand, or South Africa or any other jurisdiction in which such offer, sale, resale or delivery would be unlawful.

Market Abuse Regulation

Market soundings, as defined in the UK version ("UK MAR") of the Market Abuse Regulation No. 596/2014 ("EU MAR"), which is part of English law by virtue of the European Union (Withdrawal) Act 2018 (as amended), were taken in respect of the Placing, with the result that certain persons became aware of inside information, as permitted by UK MAR. That inside information is set out in this announcement and has been disclosed as soon as possible in accordance with paragraph 7 of article 17 of UK MAR. Therefore, those persons that received inside information in a market sounding are no longer in possession of inside information relating to the Company and its securities.

Information to Distributors 

Solely for the purposes of the product governance requirements contained within the FCA Handbook Product Intervention and Product Governance Sourcebook (the "UK Product Governance Rules"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the UK Product Governance Rules) may otherwise have with respect thereto, the Placing Shares have been subject to a product approval process, which has determined that the Placing Shares are: (i) compatible with an end target market of investors who meet the criteria of professional clients and eligible counterparties, each defined in the FCA Handbook Conduct of Business Sourcebook ("COBS"); and (ii) eligible for distribution through all distribution channels as are permitted by the UK Product Governance Rules (the "UK Target Market Assessment").

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" and/or "distributor" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Placing Shares have been subject to a product approval process, which has determined that the Placing Shares are: (i) compatible with an end target market of: (a) investors who meet the criteria of professional clients and (b) eligible counterparties (each as defined in MiFID II); and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "EU Target Market Assessment").

Notwithstanding the UK Target Market Assessment and the EU Target Market Assessment, distributors should note that: the price of the Ordinary Shares may decline and investors could lose all or part of their investment; such securities offer no guaranteed income and no capital protection; and an investment in such securities is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom.

Each of the UK Target Market Assessment and the EU Target Market Assessment is without prejudice to any contractual, legal or regulatory selling restrictions in relation to the Placing. Furthermore, it is noted that, notwithstanding the UK Target Market Assessment and the EU Target Market Assessment, Zeus Capital will only procure investors who meet the criteria of professional clients and eligible counterparties each as defined under COBS or MiFID II, as applicable.

For the avoidance of doubt, each of the UK Target Market Assessment and the EU Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of Chapters 9A or 10A respectively of COBS or MiFID II, as applicable; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Placing Shares.

Each distributor is responsible for undertaking its own target market assessment in respect of the Placing Shares and determining appropriate distribution channels.

Persons (including, without limitation, nominees and trustees) who have a contractual or other legal obligation to forward a copy of this Appendix or the Announcement of which it forms part should seek appropriate advice before taking any action.

These terms and conditions apply to persons making an offer to acquire Placing Shares and should be read in their entirety. Each Placee hereby agrees with Zeus Capital and the Company to be bound by these terms and conditions. A Placee shall, without limitation, become so bound if Zeus Capital confirms to such Placee its allocation of Placing Shares.

Upon being notified of its allocation of Placing Shares, a Placee shall be contractually committed to acquire the number of Placing Shares allocated to it at the Placing Price and otherwise on the terms and conditions set out in this Announcement and, to the fullest extent permitted by law, will be deemed to have agreed not to exercise any rights to rescind or terminate or otherwise withdraw from such commitment.

In this Appendix, unless the context otherwise requires, "Placee" means a Relevant Person (including individuals, funds or others) on whose behalf a commitment to subscribe for or acquire Placing Shares has been given.

Details of the Placing Agreement and the Placing Shares

Zeus Capital and the Company have entered into a Placing Agreement, under which Zeus Capital has, on the terms and subject to the conditions set out therein, undertaken to use its reasonable endeavours to procure subscribers for the Placing Shares at the Placing Price. The Placing is not being underwritten by Zeus Capital or any other person.

The number of the Placing Shares will be determined following completion of the Placing.  The timing of the closing of the Placing and the number and allocation of Placing Shares to Placees are at the discretion of Zeus Capital, following consultation with the Company. Allocations will be confirmed orally or by email by Zeus Capital following the close of the Placing. A further announcement confirming these details will then be made as soon as practicable following completion of the Placing.

The Placing Shares will, when issued, be subject to the Articles, will be credited as fully paid and rank pari passu in all respects with the Existing Ordinary Shares, including the right to receive all dividends and other distributions (if any) declared, made or paid on or in respect of Ordinary Shares after the date of issue of the Placing Shares.

Application for admission to trading on AIM

Application will be made to the London Stock Exchange for admission to trading on AIM of the Placing Shares.  It is expected that settlement of the Placing Shares and Admission will become effective at 8.00 a.m. on 14 August 2024 and that dealings in the Placing Shares will commence at that time.

Bookbuild Placing

Zeus Capital will today commence an accelerated bookbuilding process to determine demand for participation in the Placing by potential Placees at the Placing Price. This Appendix gives details of the terms and conditions of, and the mechanics of participation in, the Placing. No commissions will be paid to Placees or by Placees in respect of any Placing Shares.

Zeus Capital and the Company shall be entitled to effect the Placing by such alternative method to the Placing as they may, in their discretion, determine.

The principal terms of the Placing are as follows:

1.    Zeus Capital is arranging the Placing as sole agent for, and broker of, the Company.

2.    Participation in the Placing is only available to persons who are lawfully able to be, and have been, invited to participate by Zeus Capital. Zeus Capital and any of its affiliates are entitled to participate in the Bookbuild.

3.    The Bookbuild, if successful, will establish the number of Placing Shares to be issued at the Placing Price, which will be determined by Zeus Capital, in consultation with the Company, following completion of the Placing. The results of the Placing, including the number of Placing Shares, will be announced on a Regulatory Information Service following completion of the Placing.

4.    To bid in the Placing, prospective Placees should communicate their bid by telephone or email to their usual contact at Zeus Capital. Each bid should state the number of Placing Shares which the prospective Placee wishes to subscribe for. Bids may be scaled down by Zeus Capital on the basis referred to in paragraph 1 below.

5.    The Placing is expected to close no later than 5.00 p.m. on 25 July 2024 but may be closed earlier or later subject to the agreement of Zeus Capital and the Company. Zeus Capital may, in agreement with the Company, accept bids that are received after the Bookbuild has closed.  The Company reserves the right to reduce or seek to increase the amount to be raised pursuant to the Placing, in its absolute discretion.

6.    Allocations of the Placing Shares to Placees will be determined by Zeus Capital, following consultation with the Company. Each Placee's allocation will be confirmed to Placees orally, or by email, by Zeus Capital following the close of the Placing and a trade confirmation or contract note will be dispatched as soon as possible thereafter. Oral or emailed confirmation from Zeus Capital will give rise to an irrevocable, legally binding commitment by that person (who at that point becomes a Placee), in favour of Zeus Capital and the Company, under which it agrees to acquire by subscription the number of Placing Shares allocated to it at the Placing Price and otherwise on the terms and subject to the conditions set out in this Appendix and in accordance with the Articles. Except with Zeus Capital's consent, such commitment will not be capable of variation or revocation. Zeus Capital may choose to accept bids, either in whole or in part, on the basis of allocations determined at their absolute discretion, in consultation with the Company, and may scale down any bids for this purpose on the basis referred to in paragraph 8 below. 

7.    The Company will make a further announcement following the close of the Placing detailing the results of the Placing and the number of Placing Shares to be issued at the Placing Price.

8.    Subject to paragraphs 4 and 5 above, Zeus Capital may choose not to accept bids and/or to accept bids, either in whole or in part, on the basis of allocations determined at its discretion (after consultation with the Company) and may scale down any bids for this purpose on such basis as it may determine. Zeus Capital may also, notwithstanding paragraphs 4 and 5 above, subject to the prior consent of the Company, allocate Placing Shares after the time of any initial allocation to any person submitting a bid after that time or allocate Placing Shares after the Bookbuild has closed to any person submitting a bid after that time.

9.    A bid in the Placing will be made on the terms and subject to the conditions in the Announcement (including this Appendix) and will be legally binding on the Placee on behalf of which it is made and, except with Zeus Capital's consent, will not be capable of variation or revocation from the time at which it is submitted. Following Zeus Capital's oral or written confirmation of each Placee's allocation and commitment to acquire Placing Shares, each Placee will have an immediate, separate, irrevocable and binding obligation, owed to Zeus Capital (as agent for the Company), to pay to it (or as it may direct) in cleared funds an amount equal to the product of Placing Price and the number of Placing Shares such Placee has agreed to acquire and the Company has agreed to allot and issue to that Placee.

10.  Except as required by law or regulation, no press release or other announcement will be made by Zeus Capital or the Company using the name of any Placee (or its agent), in its capacity as Placee (or agent), other than with such Placee's prior written consent.

11.  Irrespective of the time at which a Placee's allocation pursuant to the Placing is confirmed, settlement for all Placing Shares to be acquired pursuant to the Placing will be required to be made at the same time, on the basis explained below under "Registration and Settlement".

12.  All obligations of Zeus Capital under the Placing will be subject to fulfilment of the conditions referred to below "Conditions of the Placing" and to the Placing not being terminated on the basis referred to below under "Right to terminate the Placing Agreement".

13.  By participating in the Placing, each Placee agrees that its rights and obligations in respect of the Placing will terminate only in the circumstances described below and will not be capable of rescission or termination by the Placee.

14.  To the fullest extent permissible by law and the applicable rules of the FCA, neither Zeus Capital, nor the Company, nor any of their respective affiliates, agents, directors, officers or employees shall have any liability to Placees (or to any other person whether acting on behalf of a Placee or otherwise whether or not a recipient of these terms and conditions) in respect of the Placing. In particular, neither Zeus Capital, nor the Company, nor any of their respective affiliates, agents, directors, officers or employees shall have any liability (including to the extent permissible by law, any fiduciary duties) in respect of Zeus Capital's conduct of the Placing or of such alternative method of effecting the Placing as Zeus Capital and the Company may determine.

15.  The Placing is not subject to any minimum fundraising and no element of the Placing is underwritten by Zeus Capital or any other person.

Conditions of the Bookbuild Placing

The Placing is conditional upon the Placing Agreement becoming unconditional and not having been terminated in accordance with its terms.

Zeus Capital's obligations under the Placing Agreement are conditional on:

1.    the entering into of the Acquisition Agreement;

2.    the fulfilment by the Company of its obligations to deliver to Zeus Capital certain documents required under the Placing Agreement by the time specified in the Placing Agreement;

3.    an AIM application form in respect of the Placing Shares signed on behalf of the Company and all other documents to be submitted therewith having been delivered to the London Stock Exchange;

4.    the Circular having been posted to the Company's shareholders by no later than 25 July 2024 (by first class pre-paid mail) in accordance with the articles of association;

5.    the Company having complied with all of its other obligations under the Placing Agreement (to the extent that such obligations fall to be performed prior to Admission) and not being in breach of the Placing Agreement save where, in the good faith opinion of Zeus Capital, such non-compliance or breach is not material;

6.    no matter having arisen before Admission which would reasonably be expected to give rise to a claim under any of the indemnities given by the Company in the Placing Agreement;

7.    the Resolutions being passed at the General Meeting;

8.    the Acquisition Agreement not having been terminated prior to Admission;

9.    the delivery by the Company to Zeus Capital immediately prior to Admission of the warranty certificate in the form set out in the Placing Agreement and signed for and on behalf of the Company by a Director;

10.  the Placing Shares having been allotted, subject only to Admission; and

11.  Admission having occurred not later than 8.00 a.m. on 14 August 2024 or such later date as the Company and the Bank may agree, but in any event not later than 8.00 a.m. on 23 September 2024 (the "Long Stop Date").

If: (i) any of the conditions contained in the Placing Agreement, including those described above, are not fulfilled or (where applicable) waived by Zeus Capital by the respective time or date where specified (or such later time or date as Zeus Capital may notify to the Company, being not later than the Long Stop Date; (ii) any of such conditions becomes incapable of being fulfilled; or (iii) the Placing Agreement is terminated in the circumstances specified below, the Placing will not proceed and the Placees' rights and obligations hereunder in relation to the Placing Shares shall cease and terminate at such time and each Placee agrees that no claim can be made by the Placee in respect thereof.

Zeus Capital may, at its discretion and upon such terms as it thinks fit, waive, or extend the period for (subject to the Long Stop Date), compliance by the Company with the whole or any part of any of the Company's obligations in relation to the conditions in the Placing Agreement, save that the conditions relating to Admission taking place may not be waived. Any such extension or waiver will not affect Placees' commitments as set out in this Announcement.

Neither Zeus Capital nor the Company nor any of their respective affiliates, agents, directors, officers or employees shall have any liability to any Placee (or to any other person whether acting on behalf of a Placee or otherwise) in respect of any decision they may make as to whether or not to waive or to extend the time and/or date for the satisfaction of any condition to the Placing nor for any decision they may make as to the satisfaction of any condition or in respect of the Placing generally and, by participating in the Placing, each Placee agrees that any such decision is within the absolute discretion of Zeus Capital.

Right to terminate the Placing Agreement

Zeus Capital is entitled, at any time before Admission, to terminate the Placing Agreement by giving notice to the Company in certain circumstances, including, inter alia:

1.    the Company fails to comply with any of its obligations under the Placing Agreement which Zeus Capital reasonably considers to be material; or

2.    it comes to the notice of Zeus Capital that any statement contained in any of the Issue Documents (as defined in the Placing Agreement) was untrue, incorrect or misleading at the date of such document in any respect which Zeus Capital reasonably considers to be material; or

3.    it comes to the notice of the Bank that any statement contained in any of the Issue Documents (as defined in the Placing Agreement) has become untrue, incorrect or misleading in any respect which Zeus Capital reasonably considers to be material or any matter which Zeus Capital reasonably considers to be material has arisen which would, if the Placing were made at that time, constitute a material omission therefrom; or

4.    it comes to the notice of Zeus Capital that any of the warranties given by the Company was not at the date of the Placing Agreement true and accurate in any respect which Zeus Capital reasonably considers to be material by reference to the facts subsisting at the time when the notice referred to below is given; or

5.    it comes to the notice of Zeus Capital that a matter has arisen which is reasonably likely to give rise to a claim under any of the indemnities given by the Company in the Placing Agreement which Zeus Capital reasonably considers to be material by reference to the facts subsisting at the time when the notice referred to below is given; or

6.    any of the warranties, given by the Company by reference to the circumstances prevailing from time to time has ceased to be true and accurate in any respect which Zeus Capital reasonably considers to be material by reference to the facts subsisting at the time when the notice referred to below is given; or

7.    it comes to the notice of Zeus Capital that there has been, or will be a breach of the Acquisition Agreement including any of the warranties in that agreement which Zeus Capital reasonably considers to be material or the Acquisition Agreement is otherwise terminated, rescinded or frustrated, then Zeus Capital may, after having to the extent practicable in the circumstances consulted with the Company, give notice in writing to the Company prior to Admission to terminate its obligations under the Placing Agreement.

The rights and obligations of the Placees will not be subject to termination by the Placees or any prospective Placees at any time or in any circumstances. By participating in the Placing, Placees agree that the exercise by Zeus Capital of any right of termination or other discretion under the Placing Agreement shall be within the absolute discretion of Zeus Capital and that Zeus Capital need not make any reference to Placees in this regard and that neither Zeus Capital nor any of its respective affiliates shall have any liability to Placees whatsoever in connection with any such exercise or failure so to exercise.

No Admission Document or Prospectus

The Placing Shares are being offered to a limited number of specifically invited persons only and have not been nor will they be offered in such a way as to require the publication of a prospectus in the United Kingdom or in any other jurisdiction. No offering document, admission document or prospectus has been or will be submitted to be approved by the FCA or the London Stock Exchange in relation to the Placing or the Placing Shares, and Placees' commitments will be made solely on the basis of the information contained in the Announcement (including this Appendix) and the Publicly Available Information and subject to any further terms set out in the contract note, electronic trade confirmation or other (oral or written) confirmation to be sent to individual Placees.  Each Placee, by accepting a participation in the Placing, agrees that the content of this Announcement is exclusively the responsibility of the Company and confirms that it has not relied on any other information (other than the Publicly Available Information), representation, warranty, or statement made by or on behalf of the Company or Zeus Capital or any other person and neither Zeus Capital, the Company nor any other person will be liable for any Placee's decision to participate in the Placing based on any other information, representation, warranty or statement which the Placees may have obtained or received and, if given or made, such information, representation, warranty or statement must not be relied upon as having been authorised by Zeus Capital, the Company or their respective officers, directors, employees or agents. Each Placee acknowledges and agrees that it has relied on its own investigation of the business, financial or other position of the Company in accepting a participation in the Placing. Neither the Company nor Zeus Capital are making any undertaking or warranty to any Placee regarding the legality of an investment in the Placing Shares by such Placee under any legal, investment or similar laws or regulations. Each Placee should not consider any information in this Announcement to be legal, tax or business advice. Each Placee should consult its own solicitor, tax adviser and financial adviser for independent legal, tax and financial advice regarding an investment in the Placing Shares. Nothing in this paragraph shall exclude the liability of any person for fraudulent misrepresentation.

Registration and Settlement

Following closure of the Placing, each Placee allocated Placing Shares in the Placing will be sent a trade confirmation or contract note in accordance with the standing arrangements in place with Zeus Capital, stating the number of Placing Shares allocated to it at the Placing Price, the aggregate amount owed by such Placee (in pounds sterling) and a form of confirmation in relation to settlement instructions.

Each Placee will be deemed to agree that it will do all things necessary to ensure that delivery and payment is completed as directed by Zeus Capital in accordance with the standing CREST settlement instructions which they have in place with Zeus Capital.

Settlement of transactions in the Placing Shares (ISIN: GB00BLF79J41) following Admission will take place within CREST provided that, subject to certain exceptions.  Settlement through CREST is expected to occur on or around 14 August 2024 (the "Settlement Date") in accordance with the contract note, electronic trade confirmation or other (oral or written) confirmation. Settlement will be on a delivery versus payment basis.  However, in the event of any difficulties or delays in the admission of the Placing Shares to CREST or the use of CREST in relation to the Placing, the Company and Zeus Capital may agree that the Placing Shares should be issued in certificated form.  Zeus Capital reserve the right to require settlement for the Placing Shares, and to deliver the Placing Shares to Placees, by such other means as they deem necessary if delivery or settlement to Placees is not practicable within the CREST system or would not be consistent with regulatory requirements in the jurisdiction in which a Placee is located.

Interest is chargeable daily on payments not received from Placees on the due date(s) in accordance with the arrangements set out above at the rate of 4 percentage points above the prevailing Bank of England base rate as determined by Zeus Capital.

Subject to the conditions set out above, payment in respect of the Placees' allocations is due as set out below. Each Placee should provide its settlement details in order to enable instructions to be successfully matched in CREST.

The relevant settlement details for the Placing Shares are as follows:

Each Placee is deemed to agree that, if it does not comply with these obligations, Zeus Capital may sell any or all of the Placing Shares allocated to that Placee on such Placee's behalf and retain from the proceeds, for Zeus Capital's account and benefit (as agent for the Company), an amount equal to the aggregate amount owed by the Placee plus any interest due. The relevant Placee will, however, remain liable and shall indemnify Zeus Capital on demand for any shortfall below the aggregate amount owed by it and may be required to bear any stamp duty or stamp duty reserve tax or securities transfer tax (together with any interest or penalties) which may arise upon the sale of such Placing Shares on such Placee's behalf. By communicating a bid for Placing Shares, each Placee confers on Zeus Capital such authorities and powers necessary to carry out any such sale and agrees to ratify and confirm all actions which Zeus Capital lawfully takes in pursuance of such sale. Legal and/or beneficial title in and to any Placing Shares shall not pass to the relevant Placee until it has fully complied with its obligations hereunder.

If Placing Shares are to be delivered to a custodian or settlement agent, Placees should ensure that the form of confirmation is copied and delivered immediately to the relevant person within that organisation.

Insofar as Placing Shares are registered in a Placee's name or that of its nominee or in the name of any person for whom a Placee is contracting as agent or that of a nominee for such person, such Placing Shares should, subject as provided below, be so registered free from any liability to UK stamp duty or stamp duty reserve tax or securities transfer tax. Neither Zeus Capital nor the Company will be liable in any circumstances for the payment of stamp duty, stamp duty reserve tax or securities transfer tax in connection with any of the Placing Shares. Placees will not be entitled to receive any fee or commission in connection with the Placing.

Representations, Warranties and Further Terms

By participating in the Placing, each Placee (and any person acting on such Placee's behalf) irrevocably makes the following representations, warranties, acknowledgements, agreements and undertakings (as the case may be) to Zeus Capital for itself and on behalf of the Company:

1.    that it has read and understood this Announcement, including this Appendix, in its entirety and that its subscription for Placing Shares is subject to and based upon all the terms, conditions, representations, warranties, acknowledgements, agreements and undertakings and other information contained herein and undertakes not to redistribute or duplicate this Announcement;

2.    it has not received and will not receive a prospectus or other offering document in connection with the Placing and acknowledges that no prospectus or other offering document:

a.    is required under the UK Prospectus Regulation or other applicable law; and

b.    has been or will be prepared in connection with the Placing;

3.    that its obligations are irrevocable and legally binding and shall not be capable of rescission or termination by it in any circumstances;

4.    that the exercise by Zeus Capital of any right or discretion under the Placing Agreement shall be within the absolute discretion of Zeus Capital, and Zeus Capital need not have any reference to it and shall have no liability to it whatsoever in connection with any decision to exercise or not to exercise any such right and each Placee agrees that it has no rights against Zeus Capital or the Company, or any of their respective officers, directors, employees agents or advisers, under the Placing Agreement pursuant to the Contracts (Rights of Third Parties Act) 1999;

5.    that these terms and conditions represent the whole and only agreement between it, Zeus Capital and the Company in relation to its participation in the Placing and supersedes any previous agreement between any of such parties in relation to such participation. Accordingly, each Placee, in accepting its participation in the Placing, is not relying on any information or representation or warranty in relation to the Company or any of its subsidiaries or any of the Placing Shares other than as contained in this Announcement and the Publicly Available Information, such information being all that it deems necessary to make an investment decision in respect of the Placing Shares. Each Placee agrees that neither the Company, nor Zeus Capital, nor any of their respective officers, directors or employees will have any liability for any such other information, representation or warranty, express or implied;

6.    that in the case of any Placing Shares acquired by it as a financial intermediary, as that term is used in Article 5(1) of the EU Prospectus Regulation and Article 5(1) of the UK Prospectus Regulation, (i) the Placing Shares acquired by it in the Placing have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Member State of the European Economic Area which has implemented the EU Prospectus Regulation or the UK, respectively, other than Qualified Investors or in circumstances in which the prior consent of Zeus Capital has been given to the offer or resale; or (ii) where Placing Shares have been acquired by it on behalf of persons in any member state of the EEA, or the UK respectively, other than Qualified Investors, the offer of those Placing Shares to it is not treated under the EU Prospectus Regulation or the UK Prospectus Regulation as having been made to such persons;

7.    that neither it nor, as the case may be, its clients expect Zeus Capital to have any duties or responsibilities to such persons similar or comparable to the duties of "best execution" and "suitability" imposed by the FCA's Conduct of Business Source Book, and that Zeus Capital is not acting for it or its clients, and that Zeus Capital will not be responsible for providing the protections afforded to customers of Zeus Capital or for providing advice in respect of the transactions described herein;

8.    that it has made its own assessment of the Placing Shares and has relied on its own investigation of the business, financial or other position of the Company in accepting a participation in the Placing and that it shall not be entitled to rely upon any material regarding the Placing Shares or the Company (if any) that Zeus Capital or the Company or any of their respective affiliates, agents, directors, officers or employees or any person acting on behalf of any of them has provided, other than the information in this Announcement and the Publicly Available Information; nor has it requested any of Zeus Capital, the Company or any of their respective affiliates, agents, directors, officers or employees or any person acting on behalf of any of them to provide it with any such information;

9.    that it is: (i) located outside the United States and is not a US Person as defined in Regulation S under the Securities Act ("Regulation S") and is subscribing for and/or purchasing the Placing Shares only in "offshore transactions" as defined in and pursuant to Regulation S, and (ii) it is not subscribing for and/or purchasing Placing Shares as a result of any "directed selling efforts" as defined in Regulation S or by means of any form of "general solicitation" or "general advertising" as such terms are defined in Regulation D under the Securities Act;

10.  it is not taking up the Placing Shares as a result of any "general solicitation" or "general advertising" efforts (as those terms are defined in Regulation D under the Securities Act) or any "directed selling efforts" (as such term is defined in Regulation S under the Securities Act);

11.  that the Placing Shares have not been and will not be registered under the Securities Act, or under the securities legislation of, or with any securities regulatory authority of, any state or other jurisdiction of the United States and accordingly the Placing Shares may not be offered, sold, pledged, resold, transferred, delivered or distributed into or within the United States except in compliance with the registration requirements of the Securities Act and applicable state securities requirements or pursuant to exemptions therefrom;

12.  it understands that:

a.    the Placing Shares are "restricted securities" within the meaning of Rule 144(a)(3) of the Securities Act and will be subject to restrictions on resale and transfer subject to certain exceptions under US law;

b.    no representation is made as to the availability of the exemption provided by Rule 144 of the Securities Act for resales or transfers of Placing Shares; and

c.     it will not deposit the Placing Shares in an unrestricted depositary receipt programme in the United States or for US persons (as defined in the Securities Act);

13.  it will not offer, sell, transfer, pledge or otherwise dispose of any Placing Shares except:

a.    in an offshore transaction in accordance with Rules 903 or 904 of Regulation S under the Securities Act; or

b.    pursuant to another exemption from registration under the Securities Act, if available,

c.     and in each case in accordance with all applicable securities laws of the states of the United States and other jurisdictions;

14.  no representation has been made as to the availability of the exemption provided by Rule 144, Rule 144A or any other exemption under the Securities Act for the reoffer, resale, pledge or transfer of the Placing Shares;

15.  it understands that the Placing Shares are expected to be issued to it through CREST but may be issued to it in certificated, definitive form and acknowledges and agrees that the Placing Shares may, to the extent they are delivered in certificated form, bear a legend to the following effect unless agreed otherwise with the Company:

16.  it understands that there may be certain consequences under United States and other tax laws resulting from an investment in the Placing and if applicable it has made such investigation and has consulted its own independent advisers or has otherwise satisfied itself concerning, without limitation, the effects of United States federal, state and local income tax laws and foreign tax laws generally;

17.  that the only information on which it is entitled to rely on and on which it has relied in committing to subscribe for the Placing Shares is contained in this Announcement and the Publicly Available Information, such information being all that it deems necessary to make an investment decision in respect of the Placing Shares and it has made its own assessment of the Company, the Placing Shares and the terms of the Placing based on this Announcement and the Publicly Available Information only;

18.  that neither Zeus Capital, nor the Company, nor any of their respective affiliates, agents, directors, officers or employees has made any representation or warranty to it, express or implied, with respect to the Company, the Placing or the Placing Shares or the accuracy, completeness or adequacy of the Publicly Available Information;

19.  that, unless specifically agreed with Zeus Capital, it is not and was not acting on a non-discretionary basis for the account or benefit of a person located within the United States or any US Person at the time the undertaking to subscribe for and/or purchase Placing Shares was given and it is not acquiring Placing Shares with a view to the offer, sale, resale, transfer, delivery or distribution, directly or indirectly, of any Placing Shares into the United States or to any US Person and it will not reoffer, resell, pledge or otherwise transfer the Placing Shares except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and otherwise in accordance with any applicable securities laws of any state or jurisdiction of the United States;

20.  that it is not a national or resident of Australia, Canada, Japan, New Zealand, the Republic of South Africa or a corporation, partnership or other entity organised under the laws of Australia, Canada,  Japan, New Zealand, the Republic of South Africa and that it will not (unless an exemption under the relevant securities laws is applicable) offer, sell, renounce, transfer or deliver, directly or indirectly, any of the Placing Shares in Australia, Canada, Japan, New Zealand or the Republic of South Africa or to or for the benefit of any person resident in Australia, Canada, Japan, New Zealand, the Republic of South Africa and each Placee acknowledges that the relevant clearances or exemptions are not being obtained from the Securities Commission of any province or territory of Canada, that no prospectus has been or will be lodged with, filed with or registered by the Australian Securities and Investments Commission, the Canadian Securities Administrators, the Japanese Ministry of Finance, the Securities Commission of New Zealand or the South African Reserve Bank and that the Placing Shares are not being offered for sale and may not (unless an exemption under the relevant securities laws is applicable) be offered, sold, resold or delivered, directly or indirectly, in or into the United States, Australia, Canada, Japan, New Zealand, the Republic of South Africa or any other jurisdiction in which such offer, sale, resale or delivery would be unlawful;

21.  that it does not have a registered address in, and is not a citizen, resident or national of, any jurisdiction in which it is unlawful to make or accept an offer of the Placing Shares and it is not acting on a non-discretionary basis for any such person;

22.  that it has not, directly or indirectly, distributed, forwarded, transferred or otherwise transmitted, and will not, directly or indirectly, distribute, forward, transfer or otherwise transmit, any presentation or offering materials concerning the Placing or the Placing Shares to any persons within the United States or to any US Persons;

23.  that it is entitled to subscribe for and/or purchase Placing Shares under the laws of all relevant jurisdictions which apply to it and that it has fully observed such laws and obtained all governmental and other consents which may be required thereunder or otherwise and complied with all necessary formalities and that it has not taken any action which will or may result in the Company or Zeus Capital or any of their respective directors, officers, employees or agents acting in breach of any regulatory or legal requirements of any territory in connection with the Placing or its acceptance;

24.  that it has obtained all necessary consents and authorities to enable it to give its commitment to subscribe for and/or purchase the Placing Shares and to perform its subscription and/or purchase obligations;

25.  that where it is acquiring Placing Shares for one or more managed accounts, it is authorised in writing by each managed account: (a) to acquire the Placing Shares for each managed account; (b) to make on its behalf the representations, warranties, acknowledgements, undertakings and agreements in this Appendix and the Announcement of which it forms part; and (c), if applicable, to receive on its behalf any investment letter relating to the Placing in the form provided to it by Zeus Capital;

26.  that it is either: (a) a person of a kind described in paragraph 5 of Article 19 (persons having professional experience in matters relating to investments and who are investment professionals) of the Order; or (b) a person of a kind described in paragraph 2 of Article 49(2)(A) to (D) (high net worth companies, unincorporated associations, partnerships or trusts or their respective directors, officers or employees) of the Order; or (c) a person to whom it is otherwise lawful for this Announcement to be communicated and in the case of (a) and (b) undertakes that it will acquire, hold, manage or dispose of any Placing Shares that are allocated to it for the purposes of its business;

27.  that, unless otherwise agreed by Zeus Capital, it is a Qualified Investor;

28.  that, unless otherwise agreed by Zeus Capital, it is a "professional client" or an "eligible counterparty" within the meaning of Chapter 3 of the FCA's COBS and it is purchasing Placing Shares for investment only and not with a view to resale or distribution;

29.  that it has only communicated or caused to be communicated and will only communicate or cause to be communicated any invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) relating to the Placing Shares in circumstances in which section 21(1) of FSMA does not require approval of the communication by an authorised person;

30.  that any money held in an account with Zeus Capital (or its nominee) on its behalf and/or any person acting on its behalf will not be treated as client money within the meaning of the rules and regulations of the FCA. Each Placee further acknowledges that the money will not be subject to the protections conferred by the FCA's client money rules. As a consequence, this money will not be segregated from Zeus Capital's (or its nominee's) money in accordance with such client money rules and will be used by Zeus Capital in the course of its own business and each Placee will rank only as a general creditor of Zeus Capital;

31.  that it will (or will procure that its nominee will) if applicable, make notification to the Company of the interest in its Ordinary Shares in accordance with the requirements of Chapter 5 of the Disclosure Guidance and Transparency Rules of the FCA);

32.  that it is not, and it is not acting on behalf of, a person falling within subsections (6), (7) or (8) of sections 67 or 70 respectively or subsections (2) and (3) of section 93 or subsection (1) of section 96 of the Finance Act 1986;

33.  that it will not deal or cause or permit any other person to deal in all or any of the Placing Shares which it is subscribing for under the Placing unless and until Admission becomes effective;

34.  that it appoints irrevocably any director of either of Zeus Capital as its agent for the purpose of executing and delivering to the Company and/or its registrars any document on its behalf necessary to enable it to be registered as the holder of the Placing Shares;

35.  that the Announcement does not constitute a securities recommendation or financial product advice and that neither Zeus Capital nor the Company has considered its particular objectives, financial situation and needs;

36.  that it has sufficient knowledge, sophistication and experience in financial, business and investment matters as is required to evaluate the merits and risks of subscribing for or purchasing the Placing Shares and is aware that it may be required to bear, and it, and any accounts for which it may be acting, are able to bear, the economic risk of, and is able to sustain, a complete loss in connection with the Placing;

37.  that it will indemnify and hold the Company and Zeus Capital and their respective affiliates harmless from any and all costs, claims, liabilities and expenses (including legal fees and expenses) arising out of or in connection with any breach of the representations, warranties, acknowledgements, agreements and undertakings in this Appendix and further agrees that the Company and Zeus Capital will rely on the truth and accuracy of the confirmations, warranties, acknowledgements and undertakings herein and, if any of the foregoing is or becomes no longer true or accurate, the Placee shall promptly notify Zeus Capital and the Company. All confirmations, warranties, acknowledgements and undertakings given by the Placee, pursuant to this Announcement (including this Appendix) are given to Zeus Capital for itself and on behalf of the Company and will survive completion of the Placing and Admission;

38.  that time shall be of the essence as regards obligations pursuant to this Appendix;

39.  that it is responsible for obtaining any legal, financial, tax and other advice that it deems necessary for the execution, delivery and performance of its obligations in accepting the terms and conditions of the Placing, and that it is not relying on the Company or Zeus Capital to provide any legal, financial, tax or other advice to it;

40.  that all dates and times in this Announcement (including this Appendix) may be subject to amendment and that Zeus Capital shall notify it of such amendments;

41.  that (i) it has complied with its obligations under the Criminal Justice Act 1993, FSMA and UK MAR, (ii) in connection with money laundering and terrorist financing, it has complied with its obligations under the Proceeds of Crime Act 2002 (as amended), the Terrorism Act 2000 (as amended), the Terrorism Act 2006 and the Money Laundering, Terrorist Financing and Transfer of Funds (information on the Payer) Regulations 2017 (as amended) and any related or similar rules, regulations or guidelines, issued, administered or enforced by any government agency having jurisdiction in respect thereof and the Money Laundering Sourcebook of the FCA and (iii) it is not a person: (a) with whom transactions are prohibited under the Foreign Corrupt Practices Act of 1977 or any economic sanction programmes administered by, or regulations promulgated by, the Office of Foreign Assets Control of the U.S. Department of the Treasury or the United States Department of State; (b) named on the Consolidated List of Financial Sanctions Targets maintained by HM Treasury of the United Kingdom; or (c) subject to financial sanctions imposed pursuant to a regulation of the European Union or a regulation adopted by the United Nations (together, the "Regulations"); and, if making payment on behalf of a third party, that satisfactory evidence has been obtained and recorded by it to verify the identity of the third party as required by the Regulations and has obtained all governmental and other consents (if any) which may be required for the purpose of, or as a consequence of, such purchase, and it will provide promptly to Zeus Capital such evidence, if any, as to the identity or location or legal status of any person which Zeus Capital may request from it in connection with the Placing (for the purpose of complying with such Regulations or ascertaining the nationality of any person or the jurisdiction(s) to which any person is subject or otherwise) in the form and manner requested by Zeus Capital on the basis that any failure by it to do so may result in the number of Placing Shares that are to be subscribed for by it or at its direction pursuant to the Placing being reduced to such number, or to nil, as Zeus Capital may decide in its absolute discretion;

42.  that it will not make any offer to the public within the meaning of the EU Prospectus Regulation or the UK Prospectus Regulation of those Placing Shares to be subscribed for and/or purchased by it;

43.  that it will not distribute any document relating to the Placing Shares and it will be acquiring the Placing Shares for its own account as principal or for a discretionary account or accounts (as to which it has the authority to make the statements set out herein) for investment purposes only and it does not have any contract, understanding or arrangement with any person to sell, pledge, transfer or grant a participation therein to such person or any third person with respect of any Placing Shares; save that if it is a private client stock, broker or fund manager it confirms that in purchasing the Placing Shares it is acting under the terms of one or more discretionary mandates granted to it by private clients and it is not acting on an execution only basis or under specific instructions to purchase the Placing Shares for the account of any third party;

44.  that it acknowledges that these terms and conditions and any agreements entered into by it pursuant to these terms and conditions shall be governed by and construed in accordance with the laws of England and Wales and it submits (on behalf of itself and on behalf of any person on whose behalf it is acting) to the exclusive jurisdiction of the English courts as regards any claim, dispute or matter arising out of any such contract, except that enforcement proceedings in respect of the obligation to make payment for the Placing Shares (together with any interest chargeable thereon) may be taken by the Company or Zeus Capital in any jurisdiction in which the relevant Placee is incorporated or in which its assets are located or any of its securities have a quotation on a recognised stock exchange;

45.  that any documents sent to Placees will be sent at the Placees' risk. They may be sent by post to such Placees at an address notified to Zeus Capital;

46.  that Zeus Capital owes no fiduciary or other duties to any Placee in respect of any representations, warranties, undertakings or indemnities in the Placing Agreement;

47.  that Zeus Capital may, in its absolute discretion, agree to become a Placee in respect of some or all of the Placing Shares;

48.  that no prospectus or offering document has been or will be prepared in connection with the Placing and it has not received and will not receive a prospectus or other offering document in connection with the Placing or the Placing Shares;

49.  undertakes that it (and any person acting on its behalf) will make payment in respect of the Placing Shares allocated to it in accordance with this Appendix on the due time and date set out herein, failing which the relevant Placing Shares may be placed with other acquirers or sold as Zeus Capital may in its sole discretion determine and without liability to such Placee, who will remain liable for any amount by which the net proceeds of such sale falls short of the product of the Placing Price and the number of Placing Shares allocated to it and may be required to bear any stamp duty, stamp duty reserve tax or other similar taxes (together with any interest or penalties) which may arise upon the sale of such Placee's Placing Shares;

50.  that its allocation (if any) of Placing Shares will represent a maximum number of Placing Shares which it will be entitled, and required, to acquire, and that Zeus Capital and/or the Company may call upon it to acquire a lower number of Placing Shares (if any), but in no event in aggregate more than the aforementioned maximum; and

51.  that if it has received any confidential price sensitive information concerning the Company in advance of the publication of this Announcement, it has not: (i) dealt in the securities of the Company; (ii) encouraged, required, recommended or induced another person to deal in the securities of the Company; or (iii) disclosed such information to any person, prior to such information being made publicly available.

The Company, Zeus Capital and their respective affiliates will rely upon the truth and accuracy of each of the foregoing representations, warranties, acknowledgements and undertakings which are given to Zeus Capital for itself and on behalf of the Company and are irrevocable.

The provisions of this Appendix may be waived, varied or modified as regards specific Placees or on a general basis by Zeus Capital.

The agreement to settle a Placee's subscription and/or purchase (and/or the subscription of a person for whom such Placee is contracting as agent) free of stamp duty and stamp duty reserve tax depends on the settlement relating only to a subscription by it and/or such person direct from the Company for the Placing Shares in question. Such agreement assumes that the Placing Shares are not being subscribed for in connection with arrangements to issue depositary receipts or to transfer the Placing Shares into a clearance service. If there are any such arrangements, or the settlement relates to any other subsequent dealing in the Placing Shares, stamp duty or stamp duty reserve tax may be payable, for which neither the Company or Zeus Capital will be responsible, and the Placee to whom (or on behalf of whom, or in respect of the person for whom it is participating in the Placing as an agent or nominee) the allocation, allotment, issue or delivery of Placing Shares has given rise to such UK stamp duty or stamp duty reserve tax undertakes to pay such UK stamp duty or stamp duty reserve tax forthwith and to indemnify on an after-tax basis and to hold harmless the Company and Zeus Capital in the event that any of the Company and/or Zeus Capital have incurred any such liability to UK stamp duty or stamp duty reserve tax. If this is the case, each Placee should seek its own advice and notify Zeus Capital accordingly.

In addition, Placees should note that they will be liable for any stamp duty and all other stamp, issue, securities, transfer, registration, documentary or other duties or taxes (including any interest, fines or penalties relating thereto) payable outside the UK by them or any other person on the subscription or purchase by them of any Placing Shares or the agreement by them to subscribe for or purchase any Placing Shares.

References to time in this Announcement are to London time, unless otherwise stated.

All times and dates in this Announcement (including the Appendices) may be subject to amendment. Zeus Capital shall notify the Placees and any person acting on behalf of the Placees of any changes.

This Announcement has been issued by, and is the sole responsibility, of the Company. No representation or warranty express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by Zeus Capital or by any of its respective affiliates or agents as to or in relation to, the accuracy or completeness of this Announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefore is expressly disclaimed.

DEFINITIONS